Segall Bryant & Hamill, LLC Adaptive Biotechnologies Corp Transaction History

Segall Bryant & Hamill, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$6.4 - $14.73 $287,827 - $662,452	44,973 Added 42.01%	152,014 $1.23 Million
Q1 2022 May 13, 2022	BUY	$10.12 - $28.9 $2,702 - $7,716	267 Added 0.25%	107,041 $1.49 Million
Q4 2021 Feb 14, 2022	BUY	$25.17 - $36.85 $125,094 - $183,144	4,970 Added 4.88%	106,774 $3 Million
Q3 2021 Nov 03, 2021	BUY	$30.02 - $39.87 $81,294 - $107,967	2,708 Added 2.73%	101,804 $3.46 Million
Q2 2021 Aug 12, 2021	BUY	$32.22 - $44.59 $193,384 - $267,629	6,002 Added 6.45%	99,096 $4.05 Million
Q1 2021 May 13, 2021	SELL	$37.26 - $67.74 $59,094 - $107,435	-1,586 Reduced 1.68%	93,094 $3.75 Million
Q4 2020 Feb 12, 2021	SELL	$45.01 - $65.47 $80,207 - $116,667	-1,782 Reduced 1.85%	94,680 $5.6 Million
Q3 2020 Nov 13, 2020	BUY	$35.79 - $48.81 $2.51 Million - $3.42 Million	70,037 Added 265.04%	96,462 $4.69 Million
Q2 2020 Aug 14, 2020	BUY	$24.95 - $48.38 $311,251 - $603,540	12,475 Added 89.43%	26,425 $1.28 Million
Q1 2020 May 14, 2020	BUY	$16.96 - $34.16 $236,592 - $476,531	13,950 New	13,950 $387,000

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.